OKYO Pharma Set for Important Conference Presentation
In a significant announcement, OKYO Pharma Limited (NASDAQ: OKYO), a biopharmaceutical company focusing on the development of groundbreaking therapies for ocular conditions, is gearing up to present at the highly anticipated Bio International Convention. This prestigious event is slated to take place soon, with numerous industry leaders and innovators gathering to share insights and advancements.
Presentation Details to Spotlight Urcosimod
The presentation will be led by CEO Gary S. Jacob, Ph.D. He will delve into the clinical development of OKYO's leading drug candidate, urcosimod, which aims to alleviate neuropathic corneal pain (NCP). NCP is a challenging and painful condition that affects many individuals worldwide. Dr. Jacob’s discussion will provide an in-depth exploration of how urcosimod works, its development journey, and the remarkable potential it holds for those suffering from this debilitating condition.
Understanding Neuropathic Corneal Pain
Neuropathic corneal pain is characterized by extreme discomfort and sensitivity in the eyes, often leading to significant impairment in daily life. Although the exact causes of NCP are not fully understood, it is frequently associated with nerve damage in the cornea and accompanying inflammation. Currently, treatment options are limited and often only partially effective, underscoring the critical need for innovative therapies like urcosimod.
The Promise of Urcosimod
Urcosimod, initially known as OK-101, is designed as a lipid-conjugated chemerin peptide agonist, selectively targeting the ChemR23 receptor found in the eye. This novel approach aims to enhance the therapeutic effectiveness and longevity of the drug’s action within the ocular environment. Recent studies indicate that urcosimod not only possesses anti-inflammatory properties but also significantly reduces pain in models of dry eye and corneal neuropathic pain. During the presentation, current clinical trial data, including findings from a pivotal Phase 2 trial, will be highlighted.
About OKYO Pharma
OKYO Pharma Limited is dedicated to innovating therapies that address serious ocular conditions, particularly neuropathic corneal pain and dry eye disease. Their commitment to research and development empowers them to create solutions that improve quality of life for patients. With a keen focus on advancing clinical trials, OKYO Pharma is actively working toward new breakthroughs in ocular health.
Additional Conference Information
The Bio International Convention will take place over several days, providing an optimal platform for OKYO and other organizations to showcase their research. This event is not only a vital opportunity for networking but also serves as a fervent gathering for pioneering ideas in the biopharmaceutical industry. Attendees can look forward to significant insights into the latest advancements in drug development, including those aimed at treating complex ocular conditions.
Frequently Asked Questions
What is OKYO Pharma's focus?
OKYO Pharma focuses on developing innovative therapies for treating neuropathic corneal pain and dry eye disease.
Who will present at the Bio International Convention?
Dr. Gary S. Jacob, the CEO of OKYO Pharma, will present findings related to urcosimod.
What is neuropathic corneal pain?
Neuropathic corneal pain is a severe condition characterized by chronic discomfort in the eyes, often stemming from nerve damage.
What is urcosimod?
Urcosimod is a clinical drug candidate designed to treat neuropathic corneal pain and is currently in clinical trials.
Where can I learn more about OKYO Pharma?
For further information on OKYO Pharma and their developments, you can visit their website at www.okyopharma.com.
